"The CVS sale was a test as part of store remolding program. Our product did very well without an advertising and promotional campaign. We have been included for evaluation by another chain. It’s the strength of the product."
You're correct, 'was a test' are key words, but, I think, clearly imply the 200 store test is over....and therefor CVS is off.
Next and important is, "for evaluation by another chain". This seems to confirm CVS is off, lending credence to the idea that there was another 'No'. What large chain on earth, like a CVS, with around 10,000 selling units, would have said no? No chain, in their right mind, after a trial product "did very well" that I can think of.
This reminds me of Boots in the UK, with 2,485 corporate selling units in August 2018, where ActiPatch selling model was switched from OTC dislays and online sales to Rx only because of its addition to the NHS Tariff and therefor insured by National Health for users....BUT there has been little, if any, Doctor CME education that would convince them to write ActiPatch scripts. In other words, to alter the ingrained drug analgesic mindset. So what if ActiPatch is covered on the NHS Tariff, so are hundreds of pain drugs and no Physician is going to write ActiPatch, unless they know why.
To me, CVS was the best low-hanging fruit I've ever seen, but what do I know....
